Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Anesth Analg. 2012 Jul;115(1):16-21. doi: 10.1213/ANE.0b013e31824d523b. Epub 2012 Mar 30.
Rotational thromboelastometry (ROTEM®)-based FIBTEM is used perioperatively to assess the extent of fibrin polymerization in whole blood. In FIBTEM, cytochalasin D eliminates the contribution of platelets to whole blood clotting, but changing levels in fibrin(ogen) and erythrocytes may differently affect clot formation. Because dynamic changes of hematocrit are not reflected in plasma fibrinogen measurements, we hypothesized that the lack of erythrocytes in isolated plasma measurements would affect the relationship between the Clauss method and whole blood-based FIBTEM during cardiac surgery. Therefore, in the current study we investigated the influence of perioperative hematocrit changes on FIBTEM and fibrinogen measurements.
Blood samples were collected from 6 consenting healthy volunteers. FIBTEM tests were run before and after serial in vitro dilutions of whole blood with saline or autologous plasma (5:1, 2:1, and 1:1 v/v). We then evaluated the relationship between FIBTEM-maximal clot firmness (MCF) and the Clauss fibrinogen method in relation to hematocrit values before and after cardiac surgery. Pearson correlation coefficients were determined between laboratory test results and ROTEM variables.
Upon in vitro hematocrit reduction, FIBTEM-MCF was progressively decreased depending on the extent of saline dilution, but it was increased by 31% after 1:1 volume replacement with autologous plasma (P < 0.05). In samples from cardiac patients (150 measurements in 50 patients), the overall correlation coefficient between FIBTEM-MCF and plasma fibrinogen was 0.80 (P < 0.001). In hemodiluted blood samples (during surgery or at intensive care unit), FIBTEM-MCF 10 mm corresponded to plasma fibrinogen levels of 200 mg/dL. In the subgroup analysis (n = 50 each), according to hematocrit levels (<25%, ≥25% to 30%, ≥30%), plasma fibrinogen levels of 200 mg/dL corresponded to 11 mm, 10 mm, and 8 mm of FIBTEM-MCF, respectively. The correlation between FIBTEM-MCF and plasma fibrinogen was higher at lower hematocrit (<25%) than at higher hematocrit (>30%) (r = 0.88 and 0.67, respectively).
Perioperative changes in hematocrit affect the correlation between plasma fibrinogen levels and FIBTEM-MCF values. The higher correlation between FIBTEM-MCF and plasma fibrinogen with lower hematocrit (<25%) indicates that FIBTEM is a practical method to determine the need for fibrinogen replacement in bleeding patients who typically develop perioperative anemia.
旋转血栓弹性测定法(ROTEM®)基于纤维蛋白原功能试验(FIBTEM),用于评估全血中纤维蛋白聚合程度。在 FIBTEM 中,细胞松弛素 D 消除了血小板对全血凝血的贡献,但纤维蛋白原(和)和红细胞水平的变化可能会对血栓形成产生不同的影响。由于血细胞比容的动态变化没有反映在血浆纤维蛋白原测量中,我们假设在心脏手术过程中,分离血浆测量中缺乏红细胞会影响 Clauss 法和全血 FIBTEM 之间的关系。因此,在目前的研究中,我们研究了围手术期血细胞比容变化对 FIBTEM 和纤维蛋白原测量的影响。
从 6 名同意的健康志愿者中采集血液样本。在体外用生理盐水或自体血浆(5:1、2:1 和 1:1v/v)连续稀释全血前后进行 FIBTEM 测试。然后,我们评估了心脏手术后 FIBTEM-最大凝块硬度(MCF)与 Clauss 纤维蛋白原方法之间的关系与血细胞比容值的关系。在实验室测试结果和 ROTEM 变量之间确定了 Pearson 相关系数。
在体外血细胞比容降低的情况下,FIBTEM-MCF 逐渐降低,这取决于生理盐水稀释的程度,但在 1:1 体积用自体血浆替代后增加了 31%(P<0.05)。在心脏患者的样本中(50 例患者共 150 次测量),FIBTEM-MCF 与血浆纤维蛋白原之间的总体相关系数为 0.80(P<0.001)。在血液稀释样本中(手术期间或重症监护病房),FIBTEM-MCF 10mm 对应于血浆纤维蛋白原水平 200mg/dL。在亚组分析中(n=50 例),根据血细胞比容水平(<25%、≥25%至 30%、≥30%),血浆纤维蛋白原水平 200mg/dL 分别对应 FIBTEM-MCF 的 11mm、10mm 和 8mm。在较低的血细胞比容(<25%)下,FIBTEM-MCF 与血浆纤维蛋白原之间的相关性高于较高的血细胞比容(>30%)(r=0.88 和 0.67)。
围手术期血细胞比容的变化会影响血浆纤维蛋白原水平与 FIBTEM-MCF 值之间的关系。在较低的血细胞比容(<25%)下,FIBTEM-MCF 与血浆纤维蛋白原之间的相关性更高,表明 FIBTEM 是一种实用的方法,可以确定在围手术期发生贫血的出血患者中是否需要纤维蛋白原替代。